Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The programmed death 1 (PD-1) inhibitor pembrolizumab has been found to prolong progression-free and overall survival among patients with advanced melanoma. We conducted a phase 3 double-blind trial to evaluate pembrolizumab as adjuvant therapy in patients with resected, high-risk stage III melanoma. METHODS: Patients with completely resected stage III melanoma were randomly assigned (with stratification according to cancer stage and geographic region) to receive 200 mg of pembrolizumab (514 patients) or placebo (505 patients) intravenously every 3 weeks for a total of 18 doses (approximately 1 year) or until disease recurrence or unacceptable toxic effects occurred. Recurrence-free survival in the overall intention-to-treat population and in the subgroup of patients with cancer that was positive for the PD-1 ligand (PD-L1) were the primary end points. Safety was also evaluated. RESULTS: At a median follow-up of 15 months, pembrolizumab was associated with significantly longer recurrence-free survival than placebo in the overall intention-to-treat population (1-year rate of recurrence-free survival, 75.4% [95% confidence interval {CI}, 71.3 to 78.9] vs. 61.0% [95% CI, 56.5 to 65.1]; hazard ratio for recurrence or death, 0.57; 98.4% CI, 0.43 to 0.74; P<0.001) and in the subgroup of 853 patients with PD-L1-positive tumors (1-year rate of recurrence-free survival, 77.1% [95% CI, 72.7 to 80.9] in the pembrolizumab group and 62.6% [95% CI, 57.7 to 67.0] in the placebo group; hazard ratio, 0.54; 95% CI, 0.42 to 0.69; P<0.001). Adverse events of grades 3 to 5 that were related to the trial regimen were reported in 14.7% of the patients in the pembrolizumab group and in 3.4% of patients in the placebo group. There was one treatment-related death due to myositis in the pembrolizumab group. CONCLUSIONS: As adjuvant therapy for high-risk stage III melanoma, 200 mg of pembrolizumab administered every 3 weeks for up to 1 year resulted in significantly longer recurrence-free survival than placebo, with no new toxic effects identified. (Funded by Merck; ClinicalTrials.gov number, NCT02362594 ; EudraCT number, 2014-004944-37 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nonetheless, adjuvant ICT has been successful in high-risk melanoma, which led to FDA approval (189-193).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [189]
Experimental — accuracy not yet measuredIn the citing paper
“Thyroid events occur in approximately 10% of patients treated with anti-PD-1/PD-L1 monotherapy, and up to 15-20% of those treated with combination PD-1/CTLA-4 blockade (as opposed to only 5% of those treated with ipilimumab monotherapy).9,38”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [9]
In the citing paper
“Any type of irAE occurs in 80-90% of patients, with higher grade events (as categorized by the Common Terminology Criteria for Adverse Events) occurring in 15-20% of patients treated with anti-PD-1/PD-L1 monotherapy, and up to 60% of patients treated with combination of ipilimumab and nivolumab.9”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [9]
In the citing paper
“The combination of ipilimumab and nivolumab has demonstrated enhanced response rates in melanoma, lung cancer, renal cell carcinoma, and mismatch repair deficient colon cancer compared with single agent therapy, although at a cost of increased toxicities (see next section).9–11”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [9]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationPembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Self-citationNivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Self-citationFinal Version of 2009 AJCC Melanoma Staging and Classification
Balch, C. M., Gershenwald, J. E., Soong, S.-J., Thompson, J. F., Atkins, M. B., Byrd, D. R., Buzaid, A. C., Cochran, A. J., Coit, D. G., Ding, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.4799 · Cited by 4,602 · cited 2×
“AJCC denotes American Joint Committee on Cancer 2009 classification, 7th edition.(14) 0.”
BackgroundSelf-citationA Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Robert, C., Karaszewska, B., Schachter, J., Rutkowski, P., Mackiewicz, A., Stroiakovski, D., Lichinitser, M., Dummer, R., Grange, F., Mortier, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412690 · Cited by 2,701
Self-citationAdjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma
Weber, J., Mandala, M., Del Vecchio, M., Gogas, H. J., Arance, A. M., Cowey, C. L., Dalle, S., Schenker, M., Chiarion-Sileni, V., Marquez-Rodas, I., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709030 · Cited by 2,246
Self-citationAdjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
Long, G. V., Hauschild, A., Santinami, M., Atkinson, V., Mandalà, M., Chiarion-Sileni, V., Larkin, J., Nyakas, M., Dutriaux, C., Haydon, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708539 · Cited by 1,490
Self-citationCompletion Dissection or Observation for Sentinel-Node Metastasis in Melanoma
Faries, M. B., Thompson, J. F., Cochran, A. J., Andtbacka, R. H., Mozzillo, N., Zager, J. S., Jahkola, T., Bowles, T. L., Testori, A., Beitsch, P. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613210 · Cited by 1,414
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
Eggermont, A. M. M., Chiarion-Sileni, V., Grob, J.-J., Dummer, R., Wolchok, J. D., Schmidt, H., Hamid, O., Robert, C., Ascierto, P. A., Richards, J. M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1611299 · Cited by 1,318
Self-citation
Cited by
Items 401–500 of 1,000
Deep learning detection of melanoma metastases in lymph nodes
Jansen, P., Baguer, D. O., Duschner, N., Arrastia, J. L., Schmidt, M., Landsberg, J., Wenzel, J., Schadendorf, D., Hadaschik, E. N., Maaß, P., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.04.023 · Cited by 41
Self-citationTetzlaff, M. T., Adhikari, C., Lo, S., Rawson, R. V., Amaria, R. N., Menzies, A. M., Wilmott, J. S., Ferguson, P. M., Ross, M. I., Spillane, A. J., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.07.016 · Cited by 37
Self-citationImmune checkpoint inhibitors in metastatic melanoma therapy (Review)
Shah, V., Panchal, V. S., Shah, A., Vyas, B., Agrawal, S. P., & Bharadwaj, S. P. (2024) · Medicine International · doi:10.3892/mi.2024.137 · Cited by 41
“In decreasing order, the first endocrine system that is most affected by ICIs is the thyroid gland Table V. Role of predictive biomarkers and their clinical relevance.”
Verver, D., Klaveren, D. V., Franke, V., van Akkooi, A. C. J., Rutkowski, P. L., Keilholz, U., Eggermont, A. M. M., Nijsten, T. E. C., Grünhagen, D. J., & Verhoef, C. K. (2018) · British journal of surgery · doi:10.1002/bjs.10995 · Cited by 39
Self-citationIs earlier better for melanoma checkpoint blockade?
Robert, C. (2018) · Nature Medicine · doi:10.1038/s41591-018-0250-0 · Cited by 39
Self-citationFind the Flame: Predictive Biomarkers for Immunotherapy in Melanoma
Garutti, M., Bonin, S., Buriolla, S., Bertoli, E., Pizzichetta, M. A., Zalaudek, I., & Puglisi, F. (2021) · Cancers · doi:10.3390/cancers13081819 · Cited by 38
Ferrari, A., Almaraz, R. L., Réguerre, Y., Česen, M., Bergamaschi, L., Indini, A., Schneider, D. T., Godzinski, J. K., Bień, E., Stachowicz‐Stencel, T., et al. (2021) · Pediatric Blood & Cancer · doi:10.1002/pbc.28992 · Cited by 39
First line treatment of BRAF mutated advanced melanoma: Does one size fit all?
Giugliano, F., Crimini, E., Tarantino, P., Zagami, P., Uliano, J., Corti, C., Trapani, D., Curigliano, G., & Ascierto, P. A. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102253 · Cited by 39
Self-citationQu, Z., Wang, Q., Wang, H., Jiao, Y., Li, M., Wei, W., Yu, L., Zhao, Z., Zhang, T., Zhang, Y., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.783197 · Cited by 38
The Emerging Use of Immune Checkpoint Blockade in the Adjuvant Setting for Solid Tumors: A Review
Moujaess, E., Haddad, F., Eid, R., & Kourié, H. R. (2019) · Immunotherapy · doi:10.2217/imt-2019-0087 · Cited by 41
Efficacy of Immune Checkpoint Inhibitors and Age in Cancer Patients
Huang, X., Gao, P., Song, Y., Sun, J., Chen, X., Zhao, J., & Wang, Z. (2020) · Immunotherapy · doi:10.2217/imt-2019-0124 · Cited by 37
Garrett, N. F. M. D. S., da Costa, A. C. C., Ferreira, E. B., Damiani, G. B., dos Reis, P. E. D., & Vasques, C. I. (2021) · PLoS ONE · doi:10.1371/journal.pone.0255716 · Cited by 38
“EGGERMONT et al, 2018 [61] France RCT 1.”
BackgroundMethodInfluentialAdjuvant treatment for melanoma in clinical practice – Trial versus reality
de Meza, M. M., Ismail, R. K., Rauwerdink, D. J. W., van Not, O. J., van Breeschoten, J., Blokx, W. A. M., de Boer, A., van Dartel, M., Hilarius, D. L., Ellebæk, E., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.08.044 · Cited by 36
Self-citationNuclear PD-L1 promotes cell cycle progression of BRAF-mutated colorectal cancer by inhibiting THRAP3
Ma, R., Liu, Y., Che, X., Li, C., Wen, T., Hou, K., & Qu, X. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.12.017 · Cited by 38
Liu, Y., Xu, Y., Cheng, X., Lin, Y., Jiang, S., Yu, H., Zhang, Z., Lu, L., & Zhang, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.862084 · Cited by 41
Rohaan, M. W., Stahlie, E. H. A., Franke, V., Zijlker, L. P., Wilgenhof, S., van der Noort, V., van Akkooi, A. C. J., & Haanen, J. B. A. G. (2022) · BMC Cancer · doi:10.1186/s12885-022-09896-4 · Cited by 40
Immune Checkpoint Inhibitor Associated Myocarditis and Cardiomyopathy: A Translational Review
Wang, D., Bauersachs, J. K., & Berliner, D. (2023) · Biology · doi:10.3390/biology12030472 · Cited by 41
Elkrief, A., Routy, B., Derosa, L., Bolte, L. A., Wargo, J. A., McQuade, J. L., & Zitvogel, L. (2025) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-25-472902 · Cited by 43
The extent of surgery for stage III melanoma: how much is appropriate?
Franke, V., & van Akkooi, A. C. J. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30099-3 · Cited by 36
The neutrophil–lymphocyte ratio and locoregional melanoma: a multicentre cohort study
Robinson, A. V., Keeble, C. M., Lo, M. C. I., Thornton, O., Peach, H., Moncrieff, M. D., Dewar, D. J., & Wade, R. G. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02478-7 · Cited by 35
From Tank to Treatment: Modeling Melanoma in Zebrafish
Frantz, W. T., & Ceol, C. J. (2020) · Cells · doi:10.3390/cells9051289 · Cited by 38
“These clinical trials demonstrated substantial improvements in patient outcomes compared to a decade ago and are currently being extended to the adjuvant setting [8].”
BackgroundUncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint Blockade
Hu, W., Wang, G., Wang, Y., Riese, M. J., & You, M. (2020) · iScience · doi:10.1016/j.isci.2020.101580 · Cited by 38
The Status of Adjuvant and Neoadjuvant Melanoma Therapy, New Developments and Upcoming Challenges
Stege, H. M., Haist, M., Nikfarjam, U., Schultheis, M., Heinz, J., Pemler, S., Loquai, C., & Grabbe, S. (2021) · Targeted Oncology · doi:10.1007/s11523-021-00840-3 · Cited by 40
Neoadjuvant therapy for melanoma: rationale for neoadjuvant therapy and pivotal clinical trials
Witt, R. G., Erstad, D. J., & Wargo, J. A. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221083052 · Cited by 39
Schumann, K., Mauch, C., Klespe, K., Loquai, C., Nikfarjam, U., Schlaak, M. S., Akcetin, S. L., Kölblinger, P., Hoellwerth, M., Meißner, M., et al. (2022) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.18779 · Cited by 38
Self-citationImmunotherapy Resistance in Glioblastoma
Wang, E. J., Chen, J.-S., Jain, S., Morshed, R. A., Haddad, A. F., Gill, S., Beniwal, A. S., & Aghi, M. K. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.750675 · Cited by 34
“4%) continued to be associated with longer recurrence-free survival at 1 year than placebo (61%) (Eggermont et al., 2018).”
BackgroundA review of the AJCC melanoma staging system in the TNM classification (eighth edition)
Ogata, D., Namikawa, K., Takahashi, A., & Yamazaki, N. (2021) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyab022 · Cited by 34
McKean, M. A., & Amaria, R. N. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.08.011 · Cited by 34
Immune checkpoint inhibitor rechallenge in patients with immune-related myositis
Delyon, J., Brunet‐Possenti, F., Léonard-Louis, S., Arangalage, D., Baudet, M., Baroudjian, B., Lebbé, C., & Hervier, B. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2018-214336 · Cited by 34
Lü, J., Yang, J., Liang, Y., Meng, H., Zhao, J., & Zhang, X. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01453 · Cited by 36
“NCT02362594 (Eggermont et al., 2018) Yes 23 123 Phase 3 PD-1 Pembrolizumab 200 mg/dose”
InfluentialTherapeutic Development of Immune Checkpoint Inhibitors
Wang, J., Yang, T., & Xu, J. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-3266-5_23 · Cited by 35
Chute, D. F., Zhao, S. J., Strohbehn, I. A., Rusibamayila, N., Seethapathy, H. S., Lee, M. D., Zubiri, L., Gupta, S., Leaf, D. E., Rahma, O. E., et al. (2020) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2021.05.012 · Cited by 37
Fucoidan-Supplemented Diet Potentiates Immune Checkpoint Blockage by Enhancing Antitumor Immunity
Yang, J., Yang, X., Pan, W., Wang, M., Lu, Y., Zhang, J., Fang, Z., Zhang, X., Ji, Y., Bei, J., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.733246 · Cited by 42
The Role of NcRNAs to Regulate Immune Checkpoints in Cancer
Jiang, Y., Zhao, L., Wu, Y., Deng, S., Cao, P., Lei, X., & Yang, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.853480 · Cited by 35
Larkin, J., Weber, J. S., Vecchio, M. D., Gogas, H. J., Arance, A. M., Dalle, S., Cowey, C. L., Schenker, M., Grob, J., Chiarion‐Sileni, V., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.06.041 · Cited by 39
Self-citationBloemendal, M., van Willigen, W. W., Bol, K. F., Boers‐Sonderen, M. J., Bonenkamp, J. J., Werner, J. E. M., Aarntzen, E. H. J. G., Koornstra, R. H. T., de Groot, J. W. B., de Vries, I. J. M., et al. (2019) · Annals of Surgical Oncology · doi:10.1245/s10434-019-07274-2 · Cited by 34
Self-citationAdjuvant therapy for stage II melanoma: the need for further studies
Lee, R. J., Mandalà, M., Long, G. V., Eggermont, A. M. M., van Akkooi, A. C. J., Sandhu, S. K., Garbe, C., & Lorigan, P. C. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.05.003 · Cited by 33
“These trials showed a consistent benefit in relapse-free survival (RFS) and distant metastasis-free survival (DMFS) for all three treatment approaches within the patient populations studied [1–7].”
Self-citationThe molecular profile of mucosal melanoma
Mikkelsen, L. H., Maag, E., Andersen, M. K., Kruhøffer, M., Larsen, A., Melchior, L. C., Toft, P. B., von Buchwald, C., Wadt, K., & Heegaard, S. (2020) · Melanoma Research · doi:10.1097/cmr.0000000000000686 · Cited by 38
Adjuvant immunotherapy for melanoma
Thomas, D. C., & Bello, D. M. (2021) · Journal of Surgical Oncology · doi:10.1002/jso.26329 · Cited by 37
“The efficacy of pembrolizumab in the adjuvant setting was initially demonstrated in the Keynote‐054 randomized clinical trial comparing the anti‐PD‐1 monoclonal antibody to placebo in 1,019 patients with completely resected high‐risk stage III melanoma.(53) In the overall intention‐to‐treat population, the 12‐month RF…”
MethodDGKA Mediates Resistance to PD-1 Blockade
Fu, L., Li, S., Xiao, W., Yu, K., Li, S., Yuan, S., Shen, J., Dong, X., Fang, Z., Zhang, J., et al. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0216 · Cited by 36
Stein, M. K., Oluoha, O., Patel, K., & Vanderwalde, A. M. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11060518 · Cited by 37
“First, while BRAF V600 mutations predict response to targeted therapy, patients are also eligible to receive ICI in either the adjuvant [92,93] or metastatic [94–98] setting regardless of BRAF mutation status.”
BackgroundDimitriou, F., Staeger, R., Ak, M., Maissen, M., Kudura, K., Barysch, M. J., Levesque, M. P., Cheng, P. F., Dummer, R., & Mangana, J. (2021) · Cancers · doi:10.3390/cancers13122931 · Cited by 35
Aung, T. N., Shafi, S., Wilmott, J. S., Nourmohammadi, S., Vathiotis, I. A., Gavrielatou, N., Fernandez, A. I., Yaghoobi, V., Sinnberg, T. W., Amaral, T. M. S., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104143 · Cited by 35
Heudel, P., Chabaud, S., Pérol, D., Fléchon, A., Fayette, J., Combemale, P., Trédan, O., Desseigne, F., de la Fouchardière, C., Boyle, H., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2020.100044 · Cited by 32
SEOM clinical guideline for the management of cutaneous melanoma (2020)
Majem, M., Manzano, J. L., Márquez‐Rodas, I., Mujika, K., Muñoz‐Couselo, E., Pérez-Ruiz, E., de la Cruz‐Merino, L., Espinosa, E., González‐Cao, M., & Berrocal, A. (2021) · Clinical & Translational Oncology · doi:10.1007/s12094-020-02539-9 · Cited by 34
Synergistic Activation of Antitumor Immunity by a Particulate Therapeutic Vaccine
Mai, J., Li, Z., Xia, X., Zhang, J., Li, J., Liu, H., Shen, J., Ramirez, M., Li, F., Li, Z., et al. (2021) · Advanced Science · doi:10.1002/advs.202100166 · Cited by 36
Histological regression in melanoma: impact on sentinel lymph node status and survival
Aivazian, K., Ahmed, T., Sharouni, M. E., Stretch, J. R., Saw, R. P. M., Spillane, A. J., Shannon, K. F., Ch’ng, S., Nieweg, O. E., Thompson, J. F., et al. (2021) · Modern Pathology · doi:10.1038/s41379-021-00870-2 · Cited by 32
“The latter, in turn, is the most powerful predictor of melanoma survival [7] and is of great importance for selecting patients who may benefit from adjuvant drug therapy and determining clinical trial eligibility [8, 9].”
BackgroundLe, T. K., Brown, I. D., Goldberg, R., Taylor, M. T., Deng, J., Parthasarathy, V., Bordeaux, Z. A., Alphonse, M. P., Kwatra, M. M., Naranbhai, V., et al. (2022) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2022.04.020 · Cited by 33
Chacon, M. R., Enrico, D. H., Burton, J., Waisberg, F., & Videla, V. M. (2018) · JAMA Network Open · doi:10.1001/jamanetworkopen.2018.5617 · Cited by 32
Takayasu, Y., Kubo, N., Shino, M., Nikkuni, O., Ida, S., Musha, A., Takahashi, K., Hirato, J., Shirai, K., Saitoh, J., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.2614 · Cited by 32
Weber, J., Glutsch, V., Geissinger, E., Haug, L., Lock, J. F., Schneider, F., Kneitz, H., Goebeler, M., Schilling, B., & Gesierich, A. (2019) · British Journal of Dermatology · doi:10.1111/bjd.18739 · Cited by 33
Helgadóttir, H., Matikas, A., Fernebro, J., Frödin, J., Ekman, S., & Rodriguez‐Wallberg, K. A. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.114010 · Cited by 34
Minimal Clinically Important Difference (MCID) of Effect Sizes other than Mean Difference
Horita, N., Yamamoto, S., Mizuki, Y., Kawagoe, T., Mihara, T., & Yamashiro, T. (2024) · Journal of Clinical Question · doi:10.69854/jcq.2024.0016 · Cited by 39
Bensimon, A. G., Zhou, Z., Jenkins, M. D., Song, Y., Gao, W., Signorovitch, J., Krepler, C., Liu, F. X., Wang, J., & Aguiar‐Ibáñez, R. (2019) · Journal of Medical Economics · doi:10.1080/13696998.2019.1609485 · Cited by 31
You, W., Shang, B., Sun, J., Liu, X., Su, L., & Jiang, S. (2020) · Oncology Reports · doi:10.3892/or.2020.7643 · Cited by 36
“Thus far, several clinical trials have been performed to compare the treatment efficiency of anti-PD-1/PD-L1 antibodies between PD-L1-positive and -negative tumors (6-11,17,21,30-43), which are summarized in Table SI.”
Middleton, M. R., Höeller, C., Michielin, O. A., Robert, C., Caramella, C., Öhrling, K., & Hauschild, A. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0994-4 · Cited by 34
“Another interesting area for future research is the potential to give HIT-IT to patients who experience progression despite adjuvant CPI therapy, as many of these patients progress with accessible locoregional disease only.(104)”
BackgroundSelf-citationNeoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanoma
Versluis, J. M., Reijers, I. L. M., Rozeman, E. A., Menzies, A. M., van Akkooi, A. C. J., Wouters, M. W. J. M., Ch’ng, S., Saw, R. P. M., Scolyer, R. A., van de Wiel, B. A., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.02.012 · Cited by 33
Self-citationThompson, N., Stewart, G. D., Welsh, S. J., Doherty, G. J., Robinson, M. J., Neville, B. A., Vervier, K., Harris, S. R., Adams, D. J., Dalchau, K. M., et al. (2022) · BMC Cancer · doi:10.1186/s12885-021-09156-x · Cited by 32
“The first adjuvant ICI trials in patients with resected melanoma at high risk of recurrence have reported improvements in relapsefree survival [18, 19] and adjuvant checkpoint blockade is now being tested in other cancers.”
Neoadjuvant immunotherapy in gastrointestinal cancers – The new standard of care?
Petričević, B., Kabiljo, J., Zirnbauer, R., Walczak, H., Laengle, J., & Bergmann, M. M. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.05.015 · Cited by 32
Zhang, Y., Liu, B., Kotenko, S. V., & Li, W. (2022) · Medicine · doi:10.1097/md.0000000000029536 · Cited by 31
Pancreatic injury following immune checkpoint inhibitors: A systematic review and meta-analysis
Zhang, T., Wang, Y., Shi, C., Liu, X., Lv, S., Wang, X., & Li, W. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.955701 · Cited by 32
“After screening and eligibility assessment, 50 clinical trials, including 35,223 patients with malignant tumors, were selected for inclusion in this meta-analysis (Figure 1) (Baas et al., 2021; Choueiri et al., 2021; Fennell et al., 2021; Gadgeel et al., 2020; Herbst et al., 2021; Janjigian et al., 2021; Monk et al.,…”
Helgadóttir, H., Ny, L., Ullenhag, G. J., Falkenius, J., Mikiver, R., Bagge, R. O., & Isaksson, K. (2023) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djad081 · Cited by 32
“During the study period, there were 2 ongoing adjuvant studies in Sweden, including stage III melanoma, the placebo-controlled EORTC 1325/ KEYNOTE-054 (open March to July, 2016), which on a national level included 4 patients, and the nonrandomized phase IIIb study COMBI-Aplus (open October 2018 to September 2019), wit…”
BackgroundZhang, Y.-P., Chen, H., Hu, Y., Lin, L., Wen, H., Pang, D., Zhang, S., Wang, Z., & Liu, S. (2024) · Nano Letters · doi:10.1021/acs.nanolett.3c05060 · Cited by 32
Stassen, R. C., Maas, C. C. H. M., van der Veldt, A. A. M., Lo, S., Saw, R. P. M., Varey, A. H. R., Scolyer, R. A., Long, G. V., Thompson, J. F., Rutkowski, P. L., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00076-7 · Cited by 36
Self-citationPembrolizumab for the first-line treatment of non-small cell lung cancer
Ninomiya, K., & Hotta, K. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1522300 · Cited by 32
Adjuvant immunotherapy for melanoma patients: progress and opportunities
Sussman, T. A., & Ott, P. A. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.102962 · Cited by 32
Interferon-gamma signature as prognostic and predictive marker in macroscopic stage III melanoma
Versluis, J. M., Blankenstein, S. A., Dimitriadis, P., Wilmott, J. S., Elens, R., Blokx, W. A. M., van Houdt, W. J., Menzies, A. M., Schrage, Y. M., Wouters, M. W. J. M., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008125 · Cited by 31
Self-citationGrob, J., Garbe, C., Ascierto, P. A., Larkin, J., Dummer, R., & Schadendorf, D. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30596-5 · Cited by 30
Self-citationManagement of V600E and V600K BRAF-Mutant Melanoma
Haugh, A. M., & Johnson, D. B. (2019) · Current Treatment Options in Oncology · doi:10.1007/s11864-019-0680-z · Cited by 33
Iivanainen, S., & Koivunen, J. P. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020556 · Cited by 30
Toripalimab for the treatment of melanoma
Tang, B., Chi, Z., & Guo, J. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1762561 · Cited by 30
“have also been tested as neoadjuvant therapy [9,10,31].”
MethodReview of Adjuvant Therapies in Renal Cell Carcinoma: Evidence to Date
Tacconi, E. M., Tuthill, M. H., & Protheroe, A. S. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s174149 · Cited by 35
NAMPT Over-Expression Recapitulates the BRAF Inhibitor Resistant Phenotype Plasticity in Melanoma
Audrito, V., Messana, V. G., Moiso, E., Vitale, N., Arruga, F., Brandimarte, L., Gaudino, F., Pellegrino, E., Vaisitti, T., Riganti, C., et al. (2020) · Cancers · doi:10.3390/cancers12123855 · Cited by 32
Beck, L., Harel, M., Yu, S., Markovits, E., Boursi, B., Markel, G., & Geiger, T. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3752 · Cited by 34
“In agreement with Eggermont and colleagues (10), survival improved among individuals diagnosed from 2014 to 2015 compared with 2004–2013 (median OS, 18.”
BackgroundAtkinson, V. G., Robert, C., Grob, J., Gogas, H. J., Dutriaux, C., Демидов, Л. В., Gupta, A. K., Menzies, A. M., Ryll, B., Miranda, F., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2021.12.015 · Cited by 30
Self-citationTriplet Therapy in Melanoma — Combined BRAF/MEK Inhibitors and Anti-PD-(L)1 Antibodies
Dixon-Douglas, J. R., Patel, R. P., Somasundram, P. M., & McArthur, G. A. (2022) · Current Oncology Reports · doi:10.1007/s11912-022-01243-x · Cited by 33
Mishima, S., Taniguchi, H., Akagi, K., Baba, E., Fujiwara, Y., Hirasawa, A., Ikeda, M., Maeda, O., Muro, K., Nishihara, H., et al. (2019) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01498-8 · Cited by 33
Primary Cutaneous Melanoma—Management in 2024
Dixon, A. J., Sladden, M. J., Zouboulis, C. C., Popescu, C. M., Nirenberg, A., Steinman, H. K., Longo, C., Dixon, Z. L., & Thomas, J. M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13061607 · Cited by 29
“This review of recent developments in melanoma management is based on the selection of publications since 2017 that the authors considered pertinent.”
BackgroundNovel Delivery Systems for Checkpoint Inhibitors
Lamichhane, P., Deshmukh, R. R., Brown, J. K., Jakubski, S., Parajuli, P., Nolan, T. A., Raja, D. S., Badawy, M., Yoon, T., Zmiyiwsky, M., et al. (2019) · Medicines · doi:10.3390/medicines6030074 · Cited by 32
TNFSF4 (OX40L) expression and survival in locally advanced and metastatic melanoma
Roszik, J., Markovits, E., Dobosz, P., Layani, A., Slabodnik-Kaner, K., Baruch, E. N., Ben‐Betzalel, G., Grimm, E. A., Berger, R., Sidi, Y., et al. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02382-0 · Cited by 30
Longo, C., Pampena, R., Lallas, A., Kyrgidis, Α., Stratigos, A., Peris, K., Garbe, C., & Pellacani, G. (2019) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16074 · Cited by 30
Keung, E. Z.-Y., & Gershenwald, J. E. (2020) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaa012 · Cited by 42
The Role of Anti-PD-1/PD-L1 in the Treatment of Skin Cancer
Patrinely, J. R., Dewan, A. K., & Johnson, D. B. (2020) · BioDrugs · doi:10.1007/s40259-020-00428-9 · Cited by 31
Moore, M. R., Friesner, I. D., Rizk, E. M., Fullerton, B. T., Mondal, M., Trager, M. H., Mendelson, K., Chikeka, I., Kurç, T., Gupta, R., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-82305-1 · Cited by 29
Novel insights on gut microbiota manipulation and immune checkpoint inhibition in cancer (Review)
Vivarelli, S., Falzone, L., Leonardi, G. C., Salmeri, M., & Libra, M. (2021) · International Journal of Oncology · doi:10.3892/ijo.2021.5255 · Cited by 31
“Impressively, for a number of recalcitrant and otherwise uncur‐ able tumors, such as advanced melanoma (AM), metastatic melanoma (MM) or advanced non‐small cell lung cancer (NSCLC), the use of ICIs has led to a substantial long‐term remission (37,38).”
BackgroundEggermont, A. M. M., Meshcheryakov, A., Atkinson, V. G., Blank, C. U., Mandalà, M., Long, G. V., Barrow, C., Giacomo, A. M. D., Fisher, R. A., Sandhu, S. K., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.09.023 · Cited by 34
Self-citationBloemendal, M., Bol, K. F., Boudewijns, S., Gorris, M. A. J., de Wilt, J. H. W., Croockewit, S., van Rossum, M. M., de Goede, A. L., Petry, K., Koornstra, R. H. T., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.2015113 · Cited by 34
Self-citationToxicities associated with immune checkpoint inhibitors: a systematic study
Kong, X., Chen, L., Su, Z., Sullivan, R. J., Blum, S. M., Qi, Z., Liu, Y., Huo, Y., Fang, Y., Zhang, L., et al. (2023) · International Journal of Surgery · doi:10.1097/js9.0000000000000368 · Cited by 32
A surgically optimized intraoperative poly(I:C)-releasing hydrogel prevents cancer recurrence
Rwandamuriye, F. X., Evans, C. W., Wylie, B., Nörret, M., Vitali, B., Ho, D., Nguyen, D., Roper, E. A., Wang, T., Hepburn, M. S., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101113 · Cited by 33
Huang, Y., Xie, W.-J., Fan, H., & Du, J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00972 · Cited by 29
Genta, S., Araújo, D. V., Hueniken, K., Pipinikas, C., Ventura, R., Rojas, P., Jones, G., Butler, M. O., Saibil, S. D., Yu, C., et al. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.103978 · Cited by 30
Zhao, W., Zhao, F., Yang, K. G., Lu, Y., Zhang, Y., Wang, W., Xie, H., Deng, K., Yang, C., Rong, Z., et al. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28607 · Cited by 28
Resistance mechanisms in melanoma to immuneoncologic therapy with checkpoint inhibitors
Fenton, S. E., Sosman, J. A., & Chandra, S. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2019.28 · Cited by 37
Madu, M. F., Franke, V., van de Wiel, B. A., Klop, W. M. C., Jóźwiak, K., van Houdt, W. J., Wouters, M. W. J. M., & van Akkooi, A. C. J. (2019) · Melanoma Research · doi:10.1097/cmr.0000000000000643 · Cited by 28
Pal, S. K., McDermott, D. F., Atkins, M. B., Escudier, B. J., Rini, B. I., Motzer, R. J., Fong, L. H., Joseph, R. W., Oudard, S. M., Ravaud, A., et al. (2020) · British Journal of Urology · doi:10.1111/bju.15058 · Cited by 28
Farrow, N. E., Raman, V., Williams, T., Nguyen, K. Y., Tyler, D. S., & Beasley, G. M. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-08478-7 · Cited by 28
Re-evaluation of Sentinel Lymph Node Biopsy for Melanoma
Morrison, S. L., & Han, D. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00819-2 · Cited by 28
Lodde, G. C., Forschner, A., Hassel, J. C., Wulfken, L. M., Meier, F. E., Mohr, P., Kähler, K. C., Schilling, B., Loquai, C., Berking, C., et al. (2021) · Cancers · doi:10.3390/cancers13102319 · Cited by 29
“7% of nivolumab- or pembrolizumab-treated patients [16,17].”
BackgroundSelf-citationMaio, M., Blank, C. U., Necchi, A., Giacomo, A. M. D., Ibrahim, R. A., Lahn, M., Fox, B. A., Bell, R. B., Tortora, G., & Eggermont, A. M. M. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.04.035 · Cited by 30
Self-citationIn Situ Visualization of PD-L1-Specific Glycosylation on Tissue Sections
Huang, M., Zhu, L., Kang, S., Chen, F., Wei, X., Lin, L., Chen, X., Wang, W., Zhu, Z., Yang, C. J., et al. (2021) · Analytical Chemistry · doi:10.1021/acs.analchem.1c03287 · Cited by 29
Metadata
- Authors
- Eggermont, A. M. M., Blank, C. U., Mandala, M., Long, G. V., Atkinson, V., Dalle, S., Haydon, A., Lichinitser, M., Khattak, A., Carlino, M. S., Sandhu, S., Larkin, J., Puig, S., Ascierto, P. A., Rutkowski, P., Schadendorf, D., Koornstra, R., Hernandez-Aya, L., Maio, M., van den Eertwegh, A. J. M., Grob, J.-J., Gutzmer, R., Jamal, R., Lorigan, P., Ibrahim, N., Marreaud, S., van Akkooi, A. C. J., Suciu, S., & Robert, C.
- Affiliations
- Aix-Marseille Université (FR)
- From the Gustave Roussy Cancer Campus Grand Paris and University Paris-Saclay, Villejuif (A.M.M.E., C.R.), Hospices Civils de Lyon Cancer Institute, Cancer Research Center of Lyon, Lyon University, Lyon (S.D.), and Aix-Marseille University, Hôpital de la Timone, Assistance Publique–Hôpitaux de Marseille, Marseille (J.-J.G.) — all in France; Netherlands Cancer Institute–Antoni van Leeuwenhoek (C.U.B., A.C.J.A.) and VU University Medical Center (A.J.M.E.), Amsterdam, and Radboud University Medical...
- The University of Sydney (AU)
- The University of Queensland (AU)
- Edith Cowan University (AU)
- Washington University in St. Louis (US)
- University of Siena (IT)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- ORCID
- Eggermont, Alexander M.M.
- Blank, Christian U.
- Long, Georgina V.
- Atkinson, Victoria
- Dalle, Stéphane
- Haydon, Andrew
- Khattak, Adnan
- Carlino, Matteo S.
- Sandhu, Shahneen
- Larkin, James
- Puig, Susana
- Ascierto, Paolo A.
- Rutkowski, Piotr
- Schadendorf, Dirk
- Koornstra, Rutger
- Hernandez-Aya, Leonel
- Maio, Michele
- Grob, Jean-Jacques
- Gutzmer, Ralf
- Jamal, Rahima
- Lorigan, Paul
- Ibrahim, Nageatte
- Marreaud, Sandrine
- Suciu, Stefan
- Robert, Caroline
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-05-10
- Volume
- 378
- Issue
- 19
- Pages
- 1789-1801
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2797309423
- Cited by
- 1,906
- References
- 31
- Citations by year
- 2026: 131 · 2025: 171 · 2024: 207 · 2023: 204 · 2022: 236 · 2021: 308 · 2020: 307 · 2019: 250 · 2018: 87
- FWCI
- 88.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (publishedVersion)
- Pure Amsterdam UMC (submittedVersion, cc-by)
- Australasian Journal of Paramedicine (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (submittedVersion, other-oa)
- Research Explorer (The University of Manchester) (submittedVersion)
- RECERCAT (Consorci de Serveis Universitaris de Catalunya) (submittedVersion, public-domain)
- Radboud Repository (Radboud University) (submittedVersion)
- Use Siena air (University of Siena) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Funders
- Merck Sharp and Dohme
- Topics
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- pembrolizumab, adjuvant therapy, stage III melanoma, PD-1 inhibitors, PD-L1 expression, recurrence-free survival, resected melanoma, immune checkpoint inhibitors, adverse events, myositis, non-relapse mortality, overall survival, progression-free survival, high-risk melanoma, tumor recurrence prevention, safety and tolerability
- MeSH terms
- Adjuvants, Immunologic, Adult, Aged, Aged, 80 and over, Double-Blind Method, Female, Humans, Infusions, Intravenous, Male, Melanoma, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Quality of Life, Skin Neoplasms, Survival Rate, Disease-Free Survival, Kaplan-Meier Estimate, Intention to Treat Analysis, B7-H1 Antigen, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.